ISPG
INTERNATIONAL SOCIETY OF PSYCHIATRIC GENETICS

WCPG

World Congress of Psychiatric Genetics

September 13-17, 2022

Vanishing Boundaries in Psychiatry

PROGRAM BOOK

2022 WELCOME LETTER

Welcome to the 2022 World Congress of Psychiatric Genetics!

Dear Colleagues,

The International Society of Psychiatric Genetics (ISPG) warmly invites you to attend the World Congress of Psychiatric Genetics (WCPG), September 13-17, 2022 in Florence, Italy. These are exciting times in psychiatric genetics. With unprecedented data availability, thanks to international efforts, we are moving from gene-identification to understanding mechanisms of psychiatric disorders, allowing for a rethinking of psychiatric categorization and for new intervention approaches to be envisaged. The WCPG is the premier international scientific meeting for research in psychiatric genetics and related areas. Leading experts of genetics, neuroscience, and psychiatry from all over the world will be participating.

The motto of this year's WCPG is "Vanishing Boundaries in Psychiatry". With this motto, we want to give attention to the important widening and diversification of our field, such as the extension from gene-finding to biological understanding, vanishing boundaries between psychiatric and non-psychiatric disorders/diseases, between disorders and population traits, and between monogenic and polygenic disorders. We want to give attention to the widening of genetic analyses across ancestries and towards integration of rare and common variant analyses. Lastly, we would like to give attention to the trajectory from basic research to clinical application of findings.

We are excited to see our community in person, once again!

Sincerely,

2022 ISPG WCPG Program Chairs
Dr. Barbara Franke, Chair
Dr. Ole Andreassen, Co-Chair
Dr. Alessandro Serretti, Co-Chair
Dr. Palmiero Monteleone, Co-Chair

TABLE OF CONTENTS


Boehringer Ingelheim
We are hiring, join our team!
Develop breakthrough treatments for complex disorders.
Find out about new opportunities within Boehringer Ingelheim's global Computational Biology and Digital Sciences team (gCBDS): https://bit.ly/gCBDS-jobs
Discover Biberach: xplorebiberach.com
Join us to grow, collaborate, innovate and improve lives.
Apply at: careers.boehringer-ingelheim.com

2022 ISPG BOARD OF DIRECTORS

OFFICERS

President:
Jordan W. Smoller, MD, ScD
Boston, MA, USA

Vice-President:
Jehannine Austin, PhD
Vancouver, Canada

Secretary:
Naomi Wray, PhD
Brisbane, Australia

Treasurer:
James Potash, MD, MPH
Baltimore, MD, USA

BOARD MEMBERS

Sarah Bergen, PhD
Stockholm, Sweden

Lea K. Davis, PhD
Nashville, TN, USA

Barbara Franke, Prof. Dr.
Nijmegen, Netherlands

Hailiang Huang, PhD
Boston, MA, USA

Andrew McIntosh, MD
Edinburgh, United Kingdom

Sarah Medland, PhD
Queensland, Australia

Daniel Mueller, M.D., PhD
Toronto, Canada

Benjamin Neale, PhD
Boston, MA, USA

Danielle Posthuma, PhD
Amsterdam, Netherlands

Henriette Raventos, MD
San Jose, Costa Rica

Jonathan Sebat, PhD
La Jolla, CA, USA

2022 WCPG CONGRESS CHAIRS

Barbara Franke, PhD

Barbara Franke is a molecular biologist and geneticist. Her research is focused on understanding the genetic contribution to neurodevelopmental psychiatric disorders, especially ADHD and its comorbidities. Beyond gene-finding, she uses complementary approaches (bioinformatics, cell-based and small animal models, neuroimaging genetics) to map biological pathways from gene to behaviour and disease. It is her goal to make genetic information useful for improving the diagnosis, monitoring, and treatment of psychiatric disorders. Barbara holds the Chair of Molecular Psychiatry at Radboud University in Nijmegen, The Netherlands. Based at the Human Genetics and Psychiatry departments of the Radboud University Medical Center (Radboudumc), she heads the Division of Genome Research. She is also the current director of the Donders Institute for Brain, Cognition and Behaviour that unites neuroscience research across the Nijmegen campus. Barbara has been awarded an honorary Adjunct Professorship at the Goethe University in Frankfurt, Germany, and holds an honorary Skou Professorship at Aarhus University in Denmark. Furthermore, she is an elected member of the Royal Netherlands Academy of Arts and Sciences, the Royal Holland Society of Sciences and Humanities, and of Academia Europaea. Barbara is a member of the Board of Directors of ISPG, the co-lead of the Psychiatric Genomics Consortium's ADHD Working Group, and the co-lead of the ENIGMA brain imaging consortium's ADHD Working Group. She founded and coordinates the International Multicentre persistent ADHD Collaboration (IMpACT) and the ECNP Network 'ADHD across the Lifespan'.

Palmiero Monteleone, MD

Palmiero Monteleone is Full Professor of Psychiatry at the University of Salerno. He coordinates the clinical and research activities of the Eating Disorders Center of the Campania Region at the University of Naples. He has been Chair and Co-chair of the Eating Disorders Section of the World Psychiatric Association; he is Chair of the Eating Disorders Section of the European Psychiatric Association. He has been member of the ICD-11 Expert Consultation Group on the Classification of Feeding and Eating Disorders, and member of Task Force on Eating Disorders of the World Federation of Societies of Biological Psychiatry. He has been Secretary and he is President of the Italian Society of Eating Psychopathology. He is member of the editorial boards of Psychoneuroendocrinology, International Journal of Eating Disorders, Neuropsychobiology, European Eating Disorders Review, Nutrients. In 2014 he has been awarded by Expertscape as the best Italian Researcher and Clinician in the field of Eating Disorders. He participates in the International Genetic Consortium of Anorexia Nervosa, the Psychiatric Genomics Consortium and the Consortium on Lithium Genetics.

2022 WCPG CONGRESS CHAIRS

Ole A Andreassen, MD PhD

Professor in psychiatry at University of Oslo, and Director of Norwegian Centre for Mental Disease Research (NORMENT), Andreassen did his PhD in psychopharmacology at University of Bergen and his post doc training in molecular neuroscience at Massachusetts General Hospital. He finished his psychiatry residency at Oslo University Hospital, and is now attending psychiatrist at their Outpatient Clinic. His research has a translational focus, and he applies clinical, neurocognitive, and brain imaging phenotypes and molecular genetics tools to identify causes and underlying pathophysiology of mental disorders. He is currently engaged in developing multimodal stratification tools for clinical utility. Andreassen builds his research on the Nordic advantages, such as public health care system, large biobanks and lifelong health registries, and is currently focusing on gene x environment interplay and development of precision medicine approaches in psychiatry. He is co-chairing international consortia in mental disorder genetics (PGC-BD) and brain imaging (ENIGMA), and coordinates European Bipolar Disorder Network (ECNP) and Horizon2020 projects (CoMorMent, RealMent).

Alessandro Serretti, MD, PhD

Alessandro Serretti is Associate Professor of Psychiatry at Bologna University, Italy, where his is also coordinator of a research unit active in clinical and genetic studies of major psychoses. Serretti is author of more than 630 scientific papers in peer reviewed journals, on topics including Mood disorders, Schizophrenia, Genetics of Major Psychoses, Therapy and Psychopathology. He has also authored one textbook of psychiatry and given over 650 presentations at meetings. H-Index of 93. Serretti is currently Editor in Chief of International Clinical Psychopharmacology. He also serves as a reviewer for over 120 international journals, including 15 as member of the editorial board, and associate editor of Neuropsychobiology. In addition, he is a reviewer for over 80 international funding agencies, including the European Commission. Serretti has trained over 50 students, PhDs and PDs, and was recognized as a Highly Cited Researcher by Web of Science in 2019 and 2020.

2022 WCPG PROGRAM COMMITTEE

Esben Agerbo
Arpana Agrawal
Alejandro Arias-Vásquez
Aurina Arnatkeviciute
Joanna Biernacka
Anders Børglum
Elvira Bramon
Gerome Breen
Na Cai
Chi-Hua Chen
Concetta Crisafulli
Shareefa Dalvie
Lea Davis
Franziska Degenhardt
Ditte Demontis
Arianna Di Florio
Laramie Duncan
Chiara Fabbri
David Glahn
Reyna Gordon
Hailiang Huang
Christopher Hübel
Matt Hurles
Tadafumi Kato
Cathryn Lewis
Mirko Manchia
Manuel Mattheisen
Nathaniel McGregor
Divya Mehta
Niamh Mullins
Humberto Nicolini
Roel Ophoff
Peristera Paschou
Giulio Pergola
James Potash
Henriette Raventós
Angelica Ronald
F. Kyle Satterstrom
Sibylle Schwab
Jordan Smoller
Emma Sprooten
Alessio Squassina
Beate St Pourcain
Evie Stergiakouli
Ene-choo Tan
Laura Thornton
Gustavo Turecki
Evangelos Vassos
Jacob Vorstman
James Walters
Varun Warrier
Naomi Wray
Rose Mary Xavier
Zeynep Yilmaz

ISPG.NET

Thank you

2022 ECIP COMMITTEE

Sarah Bergen
Boris Chaumette
Liliana Ciobanu
J. Raymond DePaulo
Vanessa Gonçalves
Jacob Gratten
Falk Lohoff
Mirko Manchia
Christel M. Middeldorp
Marina Mihaljevic
Alessandra Minelli
Niamh Mullins
Graham Murray
Emily Olfson
Renato Polimanti
Zeynep Yilmaz
Clement Zai

2022 ISPG AWARDS COMMITTEE

Naomi Wray
Lynn DeLisi
Michael Gandal
Francis McMahon
Michael Owen
Thomas Schulze

PLENARY SPEAKERS

Kristen Brennand, Ph.D.

Kristen Brennand, PhD is the Elizabeth Mears and House Jameson Professor of Psychiatry and Professor of Genetics at Yale University School of Medicine. She first established her independent laboratory in the Pamela Sklar Division of Psychiatric Genomics at the Icahn School of Medicine at Mount Sinai in 2012, after having completed post-doctoral training at the Salk Institute for Biological Studies with Dr. Fred Gage and PhD studies at Harvard University with Dr. Douglas Melton. Dr. Brennand's research combines expertise in genom, neuroscience, and stem cells, to identify the mechanisms that underlie brain disease. Her focus lies in resolving the convergence of, and complex interplay between, the many risk variants linked to disease, towards the goal of facilitating the clinical translation of genetic findings. Dr. Brennand's work is funded by the National Institutes of Health, the New York Stem Cell Foundation, the Brain Research Foundation, and the Brain and Behavior Research Foundation. Dr. Brennand is passionate about training the next generation of rigorous scientists, compassionate physicians, and collaborative cross-disciplinary researchers. She is co-Director of the newly launched YSM Fellows Program, a recruitment and training pathway for structured promotion to faculty for postdoctoral trainees from underrepresented backgrounds. Please reach out to her if you'd like to learn more about this exciting initiative!

Marion Leboyer, M.D., Ph.D.

Marion Leboyer, M.D., Ph.D. is Professor of Psychiatry at the University of Paris Est Créteil (UPEC) in France. She is head of the DMU IMPACT (University-affiliated department of Psychiatry and Addictology (Hôpitaux Universitaires Mondor, Assistance-Publique-Hôpitaux de Paris). She also runs the laboratory "Translational NeuroPsychiatry" (http://www.imrb.inserm.fr/equipes/m-leboyer-s-jamain/) which is part of Mondor Institute for Biomedical research (IMRB, Inserm U955). Since 2007, she is the executive director of a non-profit foundation, "Fondation FondaMental" (www.fondation-fondamental.org) created by the French Ministry of Research. Dr. Leboyer has authored or co-authored more than 900 peer-reviewed international publications (H-factor = 100) and is part of the highly cited researchers since 2018 (Clarivate). She received the Inserm 2021 "Grand Prix de la Recherche". Her research efforts contributed to a better identification of genetic and environmental risk factors associated with major psychiatric disorders towards better understanding of causal mechanisms. In particular, she has contributed to the identification of associations of genetic vulnerability factors, of immune dysfunctions in mood disorders, but also of environmental risk factors as well as brain imaging abnormalities. Her goal is to develop biomarkers signatures to better identify homogenous subgroups of psychiatric disorders paving the way to mechanisms-based treatments. Within the expert center networks centers created and coordinated by Fondation FondaMental, several cohorts of patients have been followed allowing for the construction of shared observational databases and biobanks. These networks have enabled multiple collaborations within different national and international research programs. Dr Leboyer is the principal investigator of several international and national research projects funded by the National Research Agency and by the French Ministry of Health including immune signatures (using biomarkers, immune-genetic, brain imaging data), and clinical trials of immune-modulatory treatment.

Ian Maze, Ph.D.

Dr. Ian Maze completed his B.S. in Microbiology at The Ohio State University and his Ph.D. in Neuroscience at the Mount Sinai School of Medicine under the mentorship of Dr. Eric Nestler, M.D., Ph.D. He then completed his Postdoctoral Studies at the Rockefeller University under the mentorship of Dr. C. David Allis, Ph.D. before joining the faculty at the Icahn School of Medicine at Mount Sinai (ISMMS) as a Tenure-Track Assistant Professor in the Department of Pharmacology and Systems Therapeutics in 2014. Dr. Maze is currently a Howard Hughes Medical Institute Investigator and Professor of Neuroscience and Pharmacological Sciences at the ISMMS and is Director of Mount Sinai's Center for Neural Epigenome Engineering. Dr. Maze's research program is focused on investigations of chromatin regulatory mechanisms controlling neurodevelopment and disease, with an extended focus on novel roles for monoamine neurotransmitters in the direct regulation of gene expression and synaptic signaling in brain.

Sarah Medland, Ph.D.

Professor Sarah Medland is a Psychiatric and Statistical Geneticist working on Neuroimaging genetics and Mental health and is best known for her work with the ENIGMA consortium and the International Workshops on Methodology of Twin and Family Studies (held in Boulder, CO). Her work bridges Genetics, Psychology, Neuro-Imaging and applied Statistics with a focus on understanding the genetic and environmental contributions to human behaviour and disease. She serves as Secretary of the Behavior Genetics Association and currently serves on the board of directors for the International Society of Psychiatric Genetics.

PLENARY SPEAKERS

Jonathan Sebat, Ph.D.

Dr. Sebat is a the director the Beyster Center for Psychiatric Genomics and Professor of Psychiatry and Cellular and Molecular Medicine at UC San Diego. Jonathan is a leader in the field of psychiatric genetics and an expert in the genomic analysis of disease by Whole Genome Sequencing (WGS). His research has made substantial contributions to our current knowledge of the contribution of rare and de novo genetic variants to risk for psychiatric disorders. His early research on structural genetic variation (SV) led to the initial discovery of the widespread abundance of SV in the human genome. Application of SV detection methods to psychiatric disorders, including autism spectrum disorders and schizophrenia has served to elucidate the role of rare variants in these disorders. Recent genome sequencing studies in large cohorts has made significant progress in further elucidating the genetic basis of ASD and the interplay of de novo mutations, rare inherited variants and polygenic risk

INDUSTRY PLENARY PANEL

Laura Ajram, Ph.D.

Laura Ajram is a translational neuroscientist, with a BSc (Hons) in Pharmacology from Kings College London and PhD in Neuropharmacology jointly awarded from the Institute of Psychiatry, Psychology and Neuroscience and Eli Lilly & Co. With 8+ years of experience in academic, industry and clinical research settings, Laura is adept at facilitating industry-academic collaborations at all stages of the translational pipeline. Working with an extensive, global network of key opinion leaders and stakeholders across industry, the NHS, academia and the charity sector, Laura has a track record of creating impactful collaborations and convening expert groups to address key challenge areas in neuroscience medicines discovery. In 2021 Laura was awarded the ELRIG Early Career Impact Award for making a 'significant impact in the drug discovery community'. Laura is currently Partnership Lead for Neuroscience at Medicines Discovery Catapult. In this role, Laura is responsible for setting up and delivering a portfolio of high-impact Syndicates with a focus on neuroscience and mental health, including the Psychiatry Consortium. Alongside her role at MDC, Laura is an active member of the British Pharmacological Society where she recently completed a 3-year term as Trustee (non-exec director) of the Society.

PLENARY SPEAKERS

Qingqin Li, Ph.D.

Qingqin Li is currently a Senior Director for Data Science and Digital Health, Neuroscience, Janssen Research & Development. In this role, Qingqin drives scientific strategy across the Neuroscience Data Science portfolio and serves as the Data Science and Digital Health lead for several Compound Development Teams. In her nearly 25 years working in data science in the pharmaceutical industry, Qingqin has led internal research programs and external collaborations with leading academic and industry partners, integrating diverse data types including genetics, multi-omics, digital, RWE. At Janssen, she has driven pioneering Digital Health observational clinical studies for relapse prediction in major depressive disorder and schizophrenia. Qingqin is a strong advocate for consortium-driven big data efforts. She serves as Janssen's representative to the Psychiatric Genome Consortium(PGC) and works closely with PGC, International Suicide Genetics Consortium (ISGC), International League Against Epilepsy (ILAE) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) to incorporate Janssen data and clinical results into consortium wide meta-analysis efforts to increase discovery of novel genes for mental illnesses. Previously Qingqin led a team in Pharmacogenomics and Neuroscience Biomarkers, where her group was among the first in the company to implement large-scale candidate gene and genome-wide association studies for gene discovery, together with Johnson & Johnson Technology (JJT) to establish the first high-performance computing environment to enable data analysis of NGS data. Prior to joining Janssen in 2002, Qingqin was a Principal Research Scientist at Eli Lilly & Company supporting Oncology computational biology and driving transcriptome profiling platform expertise across therapeutic areas (TAs) and functional areas. She has held academic positions at the University of Chicago, Harvard Medical School/Massachusetts General Hospital, and Emory University.

Eli Stahl, Ph.D.

Eli Ayumi Stahl is a Director of Statistical Genetics at the Regeneron Genetics Center, a business unit of Regeneron. Before joining Regeneron, he was Assistant Professor in the Pamela Sklar Division of Psychiatric Genomics at Mount Sinai School of Medicine. Eli has led Psychiatric Genomics Consortium GWAS of bipolar disorder and has extensive experience in the statistical genetics of bipolar, schizophrenia, and related disorders and traits.

PLENARY SPEAKERS

Liz Tunbridge, D.Phil

Liz Tunbridge, D. Phil, is currently Director of Translational Neuroscience at Boehringer Ingelheim, having moved recently from an Associate Professor position at the University of Oxford. Her academic research uses information from genomic studies to identify potential therapeutic candidates for psychiatric disorders. She studies the impact of these targets at multiple levels - molecular, cellular, circuit and behaviour - using a collaborative and multidisciplinary approach.

IDEA COMMITTEE PLENARY PANEL

Paola Giusti-Rodriguez, Ph.D.

Dr. Paola Giusti-Rodríguez is an Assistant Professor in the Department of Psychiatry at the University of Florida. Dr. Giusti-Rodríguez grew up in San Juan, Puerto Rico, where she earned a BS in biology at the University of Puerto Rico-Rio Piedras. She completed her PhD in Cell and Developmental Biology at Harvard University, where her research focused on the molecular basis of neurodegeneration. Dr. Giusti-Rodríguez carried out her postdoctoral research with Dr. Patrick Sullivan at the University of North Carolina at Chapel Hill, where she employed the multiparental Collaborative Cross mouse population to study antipsychotic pharmacogenomics.In 2016, she was awarded a K01 Mentored Research Scientist Development Award by the National Institute of Mental Health for her work focused on functional genomics of psychiatric disorders. Her work lies at the intersection between neuroscience and functional genomics, and she aims to integrate the tools of these fields to shed light on the genetics of neuropsychiatric disorders. At UF, Dr. Giusti-Rodríguez works in the Adult Research Division and focuses on human-based studies of neurodevelopmental disorders at the Center for OCD, Anxiety and Related Disorders (COARD). Dr. Giusti Rodríguez is co-founder/co-leader of the Latin American Genomics Consortium, which seeks to increase the representation of research participants from Latinx admixed ancestry in genetic studies on psychiatric disorders.

PLENARY SPEAKERS



Hailiang Huang, Ph.D.

Dr. Hailiang Huang is an Assistant Professor in the Analytic and Translational Genetics Unit at Massachusetts General Hospital (MGH) and Harvard Medical School. He is also an Associate Member at the Broad Institute of MIT and Harvard. Hailiang has enduring interests and broad experiences in the genetics of human complex disorders. He has developed novel statistical genetics methods, performed state-of-art analyses, and led international recruitments and collaborations to elucidate the genetic mechanism underlying human complex disorders, especially autoimmune and psychiatric disorders. He has also been actively participating and leading projects in the International Inflammatory Bowel Disease Genetics Consortium and Psychiatric Genetics Consortium. He is a member of the ISPG Board of Directors. Hailiang received cross-disciplinary training combining engineering, genetics, and medicine. He earned his Ph.D. from the Department of Biomedical Engineering at the Johns Hopkins School of Medicine, supervised by Dr. Joel Bader. He completed his postdoctoral training with Dr. Mark Daly at MGH and the Broad Institute.

Olivia Matshabane, Ph.D.

Dr. Olivia Matshabane is an African Postdoctoral Training Initiative (APTI) Fellow based in the Social Networks Methods Section, led by Dr. Laura Koehly at the Social and Behavioral Research Branch, under the National Human Genome Research Institute of the U.S. National Institutes of Health. Her research explores the ethical, psychological, social, and cultural implications of neurogenetics and neuroscience research. Currently, through her work at the NIH, she is involved in a project investigating how patient communication and health behaviors reflect coping needs and strategies employed by individuals with neuropsychiatric disorders, and their families, based on receiving information about a genetic variant for their condition. Her past work at the University of Cape Town, focused on exploring the impact of genetic information on the stigma experiences of South African Xhosa people with schizophrenia and rheumatic heart disease. Additionally, she conducted research exploring preferences of feedback of individual genetic research results among South African parents of children with neurodevelopmental conditions and adults with bipolar disorder. Dr. Matshabane is also the Chair of the International Neuroethics Society's (INS) Student/Postdoc Committee and serves as a representative to the INS Board of Directors. She is a member of the NIH Anti-racism Steering Committee and the NIH Stigma Special Interest Group. She is the past Chair of the Human Heredity in Africa (H3Africa) Fellows Group, and past member of the H3Africa Ethics and Community Engagement Working Group. She received her PhD in Medicine from the University of Cape Town, her Master's in Psychology from Stellenbosch University, and her Bachelor's in Psychology from the University of the Western Cape, South Africa.

Meera Purushottam, Ph.D.

Dr Meera Purushottam is a Senior geneticist in the Department of Psychiatry at the National Institute of Mental Health and Neurosciences (NIMHANS)where she helped set up the Molecular Genetics laboratory. This laboratory has helped train many young clinicians in basic aspects of genetics. After some initial linkage and association studies the lab has now projects involving family studies with detailed clinical phenotyping alongside genetics and cell model studies. In addition, Meera has a keen interest in epigenetics and she has been involved in different projects on brain age, stress and alcohol abuse. She is in charge of the genetic testing for neuromuscular disorders as well the late onset movement disorders which is part of the clinical services offered by the laboratory.

She has mentored several MSc, PhD, DM and MD students for their theses. She was a recipient of the Fulbright Nehru Academic and Professional Excellence fellowship in 2015 which she spent at Johns Hopkins Hospital, Baltimore, USA in the laboratory of Prof Christopher Ross. In the context of neuropsychiatric illness, Dr Meera is invested in understanding the epigenetic and biological implications of genetic variants at the level of the patient, the tissue and the cell.

MING TSUANG LIFETIME ACHIEVEMENT AWARD

AWARD WINNERS

Professor Nick Martin

Nick Martin graduated with honours in Genetics from the University of Adelaide in 1972 and obtained his PhD in genetics at the University of Birmingham. In 1978 he returned to a Research Fellowship at the Australian National University where he founded the Australian Twin Registry. After 3 years in the US he returned in 1986 to the Queensland Institute of Medical Research where he heads the Genetic Epidemiology Laboratory and continues longitudinal studies with twins of a wide range of complex traits of medical and behavioural interest. Most recently he has initiated projects to recruit large patient samples for GWAS of anorexia, depression and other psychiatric and neurologic disorders. He has published over 1500 papers and is a fellow of the Australian academies of Science, Social Science, and Health and Medical Science.

Dorrett Boomsma, PhD

Dorret Boomsma (Vrije Universiteit, Amsterdam) focuses in her research on the causes of variation in human complex traits from child- to adulthood as a function of genotype and environment. To this end, she established the Netherlands Twin Register which over the past 35 years recruited >200,000 twins and family members (https://tweelingenregister.vu.nl/). With the participation of these families, > 1400 papers were realized, that show the contribution of our genotype to nearly all human phenotypes across the lifespan.

She teaches quantitative genetics and is a member of the International Statistical Genetics workshop. Boomsma supervised over 60 PhD students and her work has led to national and international recognition, including the Spinoza Prize which is the highest scientific award in the Netherlands. She initiated and participates in multiple twin- and GWAS consortia and is a member of BBMRI-NL (Biobanking and BioMolecular Resources Research Infrastructure) and Odissei (Open Data Infrastructure for Social Science and Economic Innovations). In 2022 she was a awarded an honorary degree by the Faculty of Medicine, Helsinki University. She is a member of Royal Netherlands Academy of Arts and Science and the Koninklijke Hollandsche Maatschappij der Wetenschappen.

AWARD WINNERS

THEODORE REICH YOUNG INVESTIGATOR AWARD

Lea K. Davis, Ph.D.

Lea Davis is an Associate Professor of Genetic Medicine, Psychiatry and Behavioral Sciences, and Biomedical Informatics at Vanderbilt University Medical Center. Her lab works at the intersection of genetic epidemiology, psychiatry, and medical informatics to investigate the genetic basis of a wide range of mental health conditions. She is co-PI of the PsycheMERGE network which seeks to advance precision psychiatry through pre-translational psychiatric genomics research in an electronic health record (EHR) setting. Using data extracted from medical records and linked with genomic information, Dr. Davis's group discovers how polygenic risk, rare variant risk, and environment interact to result in common psychiatric diagnoses and their comorbidities. A major effort in the Davis lab focuses on understanding the biological and environmental linkages between mental and physical health. In addition to her work in psychiatric genomics, Dr. Davis has a long-standing interest in research ethics, genomic privacy, and furthering social justice through science. She currently serves on the ISPG Ethics committee, IDEA committee, and is a member of the ISPG Board of Directors.

GERSHON PAPER AWARD

"Genetic Correlates of Phenotypic Heterogeneity in Autusm"

Varun Warrier

Varun Warrier is a postdoctoral research associate at the Department of Psychiatry, University of Cambridge. He completed his PhD in 2018 at the University of Cambridge, prior to which he completed an MPhil and an MSc at Cambridge and UCL respectively. His work focuses on trying to understand how genetics and social variables are associated with neurodevelopment and mental health conditions, predominantly in young people. In autism, Warrier's interests lie in understanding the heterogeneity in both autism and profiles of co-occurring health conditions.

AWARD WINNERS

GERSHON PAPER AWARD

"Mapping Genomic Loci Implicates Genes and Synaptic Biology in Schizophrenia"

Vassily Trubetskoy

Antonio Pardiñas

Antonio is a lecturer at the MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, and a member of the wider research team of James Walters, Michael O'Donovan and Sir Michael Owen. A former population geneticist, and still a close follower of advances in that discipline, he completed his PhD in Biology at the University of Oviedo (Spain) under the supervision of Belén López in 2014. He started working at Cardiff nearly immediately afterwards, investigating treatment resistance in schizophrenia using genome-wide approaches, collaborating closely with Sophie Legge and Elliott Rees. He currently leads a small group of ECRs working on antipsychotic pharmacogenomics. Antonio is also part of the Schizophrenia Working Group of the PGC and a co-investigator of the European Research Consortia REALMENT and PsychSTRATA.

Vassily Trubetskoy studied for his bachelor's degree in Physics at Macalester College in St. Paul Minnesota. Next, he moved to work with Dr. Nancy Cox at the University of Chicago as an analyst in the Department of Medicine, Section of Genetic Medicine, working on exome analysis of Type II Diabetes, endocrine traits, and analysis software. From there, he went on to obtain his M.Sc. in Biostatistics from the University of Michigan School of Public Health, where he worked as a research assistant with Dr. Michael Boehnke. Next, he moved to work with Dr. Stephan Ripke in the Department of Psychiatry at the Charité Universitätsmedzin-Berlin, as a part of the Psychiatric Genomics Consortium (PGC). There he worked as a part of multiple working groups on genome wide association studies of psychiatric traits such as Schizophrenia and Major Depression, and bioinformatic tooling for the analysis of GWAS and related data.

RICHARD TODD AWARD

Brett Trost

Dr. Brett Trost obtained his Ph.D. in Computer Science from the University of Saskatchewan, which is located in Western Canada, and he is currently a Research Associate in the lab of Dr. Stephen Scherer at The Hospital for Sick Children in Toronto. In addition to this most recent honour, Dr. Trost has been the recipient of numerous prestigious scholarships and fellowships. These include the Vanier Canada Graduate Scholarship and the Banting Postdoctoral Fellowship, which are the top awards offered in Canada at the graduate and post-doctoral levels, respectively. He was also one of approximately 600 young scientists worldwide selected to participate in the 2018 Lindau Nobel Laureate Meeting, which was attended by nearly 40 Nobel Laureates. In a 2020 study published in Nature, Dr. Trost and his colleagues at The Hospital for Sick Children showed, for the first time, that tandem repeat expansions play a role in the genetic etiology of autism. His current work focuses on leveraging the power of whole-genome sequencing to enhance our understanding of the roles of all types of genetic variation in autism. Going forward, Dr. Trost is interested in developing and using computational methods to improve our knowledge of the genetic determinants of human health, in particular neurodevelopmental and neuropsychiatric conditions.

HUGH GURLING FINALISTS

Julia Antonieto, Federal University of Sao Paulo
Identification of Copy Number Variation (CNV) in a Cohort of Children and Adolescents at High Risk for Psychiatric Disorders

Caroline Camilo, University of São Paulo Medical School
Identification of O-Linked N-Acetylglucosamine Transferase (OGT) Expression in Human Placentas as a Potential Biomarker of Prenatal Stress Exposure

Gabriela Chavarria-Soley, Escuela de Biologia, Universidad de Costa Rica
How Does the Public in Latin American Countries View Genetic and Genomic Data Donation for Research?

Bharath Holla, National Institute of Mental Health and Neurosciences (NIMHANS), India
Evidence for Shared Neurocognitive Deficits in Major Psychiatric Illnesses – Cross-Disorder Evaluation of Bifactor Model

Srividya Makesh, National Institute of Mental Health and Neurosciences, India
Identifying Neurodevelopmental Mechanisms Related to Valproate's Teratogenic Effects

Maryanne Mufford, University of Cape Town
The Genetic Architecture of Amygdala Nuclei

Henriette Raventós, University of Costa Rica
Repercussions of the Genomic Medicine Narrative in Psychiatry on Beliefs, Clinical Practices and Public Policy in Costa Rica: A Qualitative Study

Diego Luiz Rovaris, Institute of Biomedical Sciences, University of São Paulo
The Shared Biology Between the Growth Hormone (GH)–Insulin-Like Growth Factor (IGF)-I Axis, Neurodevelopmental and Related Neuropsychiatric Disorders

Biju Viswanath, National Institute of Mental Health and Neurosciences, India
Early Insights from the Accelerator Program for Discovery in Brain Disorders Using Stem Cells

TRAVEL AWARD WINNERS

Laila Al-Soufi Novo, Instituto de Investigación Sanitaria de Santiago de Compostela
An Analysis of the Impact of Smoking on Known Genetic Correlations between Schizophrenia and Other Traits

Azmeraw Amare, University of Adelaide
Polygenic Score Identifies Bipolar Patients Ultra-Responsive to Lithium Treatment

Diego Andrade-Brito, Yale University School of Medicine
Neuronal-Specific Methylome and Hydroxymethylome Analysis Identifies Novel Loci Associated with Alcohol Use Disorder

Natasia Courchesne-Krak, UC San Diego
Phenome-Wide Association Studies of Alcohol Variants in a Multi-Ancestral Cohort Comprising up to 3 Million Individuals

Renata Cupertino, University of Vermont
Polygenic Risk Scores for Problematic Substance Use in Adolescents: An Enigma-Addiction Study

Maria de Araujo Tavares, Universidade Federal do Rio Grande do Sul
Two Sample Unidirectional Mendelian Randomization Analysis between White Matter and ADHD

Brisa S. Fernandes, University of Texas Health Science Center at Houston
Genetic Overlap Between Alzheimer's Disease and Psychiatric Disorders: Specifying the Shared Genetic Determinants and Causality Between Alzheimer's Disease, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia

Leonard Frach, University College London
Examining Intergenerational Risk Factors for Conduct Problems Using Polygenic Scores in the Norwegian Mother, Father and Child Cohort Study

Marco Galimberti, Yale University
What is the Meaning of Hardy-Weinberg Disequilibrium Observations in a Large GWAS? Studies on Alcohol Use Disorder Genetics from the Us Million Veteran Program

Nana Matoba, University of North Carolina at Chapel Hill
Mapping Wnt-Stimulus Response eQTLs in Human Neural Progenitor Cells

Brittany Mitchell, QIMR Berghofer Medical Research Institute
Exploring the Relationship between Acne and Mental Health Disorders

Kathleen Morrill, Broad Institute
Cross-Species Genetic and Evolutionary Analysis Highlight the Relevance of Canine Compulsive Behaviors for Human Obsessive-Compulsive Disorder

EARLY CAREER INVESTIGATOR PROGRAM

TRAVEL AWARD WINNERS

Maryanne Mufford, University of Cape Town
The Genetic Architecture of Amygdala Nuclei

Ajay Nadig, Broad Institute
Common and Rare Genetic Risk Factors for Schizophrenia at Chromosome 22q Induce Convergent, Dispersed Changes in Gene Expression

Eric Poisel, Central Institute of Mental Health, Heidelberg University
Epigenetic Signatures of Smoking in Five Brain Regions

Natassia Robinson, Karolinska Institute
Cannabis, Alcohol and Substance Abuse and Risk of Schizophrenia and Bipolar Disorder in a Swedish National Register Study

Daniel Rosoff, University of Oxford
Transcriptome-Wide Association Study Examining Alcohol consumption, Tobacco smoking, and Cannabis Use Yields Insight into the Etiology of Substance Use, and Identifies Drug Repositioning Opportunities

Katie Scott, Dalhousie University
Familial Traits and Subtypes of Bipolar Disorder: A Systematic Review and Meta-Analysis

Julia Sealock, Vanderbilt University
Increased Depression Polygenic Scores Associate with Worse Antidepressant Response from Electronic Health Records

Nancy Sey, University of North Carolina at Chapel Hill
Chromatin Architecture in Addiction Circuitry Elucidates Biological Mechanisms Underlying Cigarette Smoking and Alcohol Use Traits

Andrea Vereczkei, Institute of Biochemistry and Molecular Biology, Semmelweis University
Overlapping Contribution of Forkhead Box Protein N3 (FOXN3) and Glial Cell Line-Derived Neurotrophic Factor (GDNF) Gene Variants to Different Types of Substance-Related and Addictive Behaviors

Daniel Weiner, Broad Institute
Statistical and Functional Convergence of Common and Rare Variant Risk for Autism Spectrum Disorders at Chromosome 16p

Frank Wendt, Yale School of Medicine
Empathy Polygenic Scores Associate with Posttraumatic Stress Severity in Response to Early-Life Adversity

Shuyang Yao, Karolinska Institute
Brain Cell Type Specific eQTLs and Schizophrenia

ECIP ORAL FINALISTS

Jacob Bergstedt, Institute of Environmental Medicine, Karolinska Institute
Shared Genetic Contribution to Major Depressive Disorder and Cardiovascular Disease

Arjun Bhattacharya, University of California at Los Angeles
Isoform-Level Transcriptome-Wide Association Studies Uncover Novel Biological Mechanisms Underlying Genetic Associations With Five Neuropsychiatric Traits

Alexander Hatoum, Washington University St. Louis School of Medicine
Genetic Ancestry Confounds Associations Between MRI-Derived Brain Structure and Behavior: Evidence from the Adolescent Brain Cognitive Development Study

Ajay Nadig, Broad Institute
Common and Rare Genetic Risk Factors for Schizophrenia at Chromosome 22q Induce Convergent, Dispersed Changes in Gene Expression

Omar Shanta, University of California San Diego
A Genome-Wide Association Study of Copy Number Variation across Major Psychiatric Disorders in 500,000 Individuals

ECIP POSTER FINALISTS

ECIP POSTER FINALISTS

Laila Al-Soufi Novo, Instituto de Investigación Sanitaria de Santiago de Compostela
An Analysis of the Impact of Smoking on Known Genetic Correlations between Schizophrenia and Other Traits

Jessie Baldwin, UCL London
Adverse Childhood Experiences and Mental Health: Investigating Gene-Environment Correlations and Genetic Confounding

Constantinos Constantinides, University of Bath
The Association Between Polygenic Risk for Schizophrenia and Brain Age in a Population-Based Sample of Young Adults: A Recall-By-Genotype-Based Approach

Toshiki Kono, King's College London
Accounting for Cross-Population Differences in Allele Frequency and Linkage Disequilibrium Can Improve Polygenic Risk Score Portability

Daniel Levey, Yale University School of Medicine
An International and Multi-Ancestral Genome-Wide Association Study Meta-Analysis of Cannabis Use Disorders

Yingjie Shi, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour
Linking Genetic Liabilities for Major Psychiatric Disorders and Multi-Faceted Quality of Life Outcomes in the UK Biobank Study Cohort

Morgan Sidari, QIMR Berghofer Medical Research Institute
Using Multi-Polygenic Risk Score Analyses to Predict Anorexia Nervosa Case Status

Chloe Slaney, University of Bristol
Association Between Inflammation and Cognitive Functioning: Findings From a Population-Based Cohort and Mendelian Randomization Analyses

ECIP POSTER FINALISTS

Jentien Vermeulen, Amsterdam UMC
Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study

Douglas Whightman, VU Amsterdam
Rare Variant Aggregation in 148,508 Exomes Identifies Genes Associated With Proxy Alzheimer's Disease/Dementia

Isabella Willcocks, MRC CNGG
An International, Cross-Ancestry GWAS Meta-Analysis of Treatment-Resistant Schizophrenia

Grace Woolway, Cardiff University
Schizophrenia Polygenic Risk and Experiences of Childhood Adversity: A Systematic Review and Meta-Analysis

Meeting Evaluation and Continuing Education

All meeting attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CE credit for the meeting are required to complete the evaluation. This form is available **online only**. A link to the evaluation will be emailed to attendees at the completion of the congress. All evaluations must be completed by **October 17, 2022.**

Continuing Education and Disclosures

Attendees will be eligible to receive the credit hours listed below for attending the Congress. To obtain CE credits for the congress, you must complete the post-conference meeting evaluation.

There will be a charge for registrants to obtain Physician credits. You will be prompted to pay for the CE credits during the evaluation process. Upon completion of the post-conference evaluation and attestation, your CE certificate will be emailed to you. Please note, this email will often go to spam. If you do not receive your certificate, please email info@ispg.net

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Society of Psychiatric Genetics. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 24.00 *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician Assistants

PAs may claim a maximum of 24.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 24.00 hours.

Thank You

The International Society of Psychiatric Genetics would like to thank the following sponsors for their support of this year's Congress.

Silver Sponsor

Boehringer Ingelheim

RGC™

Regeneron Genetics Center

REGENERON

science to medicine®

Save the Date!

2023 World Congress of Psychiatric Genetics

October 10-14, 2023 | Montreal, Canada